<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667429</url>
  </required_header>
  <id_info>
    <org_study_id>HEC83518-P-02 / CRC-C2048</org_study_id>
    <nct_id>NCT04667429</nct_id>
  </id_info>
  <brief_title>the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets</brief_title>
  <official_title>A Phase I,Double-Blind, Placebo-Controlled, Multiple Oral Dose, Safety, Tolerability, Pharmacokinetics and Food Effect Study of HEC83518 Tablets in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple Dose Safety, Tolerability, PK ，PD and Food Effect Study of HEC83518 in Healthy&#xD;
      Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Ascending Multiple Dose Study is Double-blind design; Food Effect Study is open-label design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>up to 34 days</time_frame>
    <description>To assess the safety and tolerability of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUC) from time zero to infinity(AUC0-∞ )</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration ( Cmax)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak(tmax)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life(t½)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution(Vz/F)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Residence Time#(MRT)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent Clearance (CL/F)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Accumulation Ratio(R)</measure>
    <time_frame>up to 60 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on the Cmax</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on the AUC</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Karolinska sleepiness Scale（KSS）</measure>
    <time_frame>up to 24 hour</time_frame>
    <description>This is a 9-point scale (1 = extremely alert, 3 = alert, 5 = neither alert nor sleepy,7 = sleepy - but no difficulty remaining awake,and 9 = extremely sleepy - fighting sleep).The score of KSS scale will be recorded at different time and the change score compared with baseline will be analysed to evaluated the start of effective time, the most effective time and the recovered time to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Latency to sleep measured by a polysomnograph</measure>
    <time_frame>during the sleep time on the night(from 22:00-22:30 to the next morning wake-up)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Wake After Sleep Onset measured by a polysomnograph</measure>
    <time_frame>during the sleep time on the night(from 22:00-22:30 to the next morning wake-up)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total sleep time measured by a polysomnograph</measure>
    <time_frame>during the sleep time on the night(from 22:00-22:30 to the next morning wake-up)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sleep efficiency measured by a polysomnograph</measure>
    <time_frame>during the sleep time on the night(from 22:00-22:30 to the next morning wake-up)</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Food effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC83518 40mg will be administered fasted, or with high-fat meal for once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses-HEC83518 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC83518 20mg will be administered before sleep for 15 days .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses-HEC83518 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC83518 40mg will be administered before sleep for 15 days .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses-HEC83518 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC83518 80mg will be administered before sleep for 15 days .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered before sleep for 15 days .</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food</intervention_name>
    <description>HEC83518 40mg will be taken orally fasted or with food</description>
    <arm_group_label>Food effect</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC83518</intervention_name>
    <description>HEC83518 will be taken orally before sleep for 15 days</description>
    <arm_group_label>Multiple Ascending Doses-HEC83518 20mg</arm_group_label>
    <arm_group_label>Multiple Ascending Doses-HEC83518 40mg</arm_group_label>
    <arm_group_label>Multiple Ascending Doses-HEC83518 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The placebo will be administered before sleep for 15 days.</description>
    <arm_group_label>Multiple Ascending Doses-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are willing and are able to provide a written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          2. Without Plan for pregnancy or pregnant within 3 months after enrollment throughout the&#xD;
             trial.&#xD;
&#xD;
          3. Subjects aged between 18 and 45 (both inclusive) years old.&#xD;
&#xD;
          4. Healthy volunteers have a body weight ≥50 kg (for male) or ≥ 45kg (for female) and&#xD;
             body mass index ≥18 and ≤28 kg/m2 at screening.&#xD;
&#xD;
          5. Subjects, who are healthy, as having no clinically significant abnormalities in vital&#xD;
             signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a heart rate ≥100 beats per minute or ≤ 60 beats per minute at screening&#xD;
             or baseline.&#xD;
&#xD;
          2. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP&#xD;
             antibodies at screening.&#xD;
&#xD;
          3. Subjects with history of digestive system,urinary system, liver,central nervous&#xD;
             system, blood system, endocrine system,respiratory system,immune system,cardiovascular&#xD;
             system,and/or malignant tumor or others medical conditions (such as history of mental&#xD;
             illness, etc.) that are not suitable for clinical trial participation;Subjects with&#xD;
             history of stroke, epilepsy, bipolar disorder/mania, high intraocular pressure, or&#xD;
             acute angular-closure glaucoma.&#xD;
&#xD;
          4. Subjects with history of sleep-related illness.&#xD;
&#xD;
          5. Subjects with history of severe involuntary hypoglycemia&#xD;
&#xD;
          6. Known allergic reactions or hypersensitivity to any excipient of the drug&#xD;
             formulation(s) ,or anaphylaxis physique.&#xD;
&#xD;
          7. Use of any prescription or non-prescription medications within 14 days prior to&#xD;
             initial dosing,or Use of any medications known to inhibit or induce cytochrome P&#xD;
             enzyme drug metabolism within 28 days prior to initial dosing.&#xD;
&#xD;
          8. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit&#xD;
             within 48 hours prior to initial dosing.&#xD;
&#xD;
          9. Positive results from urine drug screen test.&#xD;
&#xD;
         10. History of alcoholism or drink regularly within 3 months prior to the study(defined as&#xD;
             Alcohol consumption of &gt; 21 units/week), or positive results from alcohol breath test.&#xD;
&#xD;
         11. Regular smoking of more than 10 cigarettes per day within 3 months before&#xD;
             administration of study drug.&#xD;
&#xD;
         12. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.&#xD;
&#xD;
         13. Subjects who plan to receive or have had organ transplants.&#xD;
&#xD;
         14. Females who are lactating/breastfeeding, or positive result from pregnancy test for&#xD;
             women of child-bearing potential. 15 Subjects who participated in another clinical&#xD;
             trial within 3 months prior to initial dosing.&#xD;
&#xD;
        16.Any other condition with in the opinion of the investigator would render the patient&#xD;
        unsuitable for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YanMei Liu, MS</last_name>
    <phone>021-54030254</phone>
    <email>ymliu@shxh-centerlab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YanMei Liu, MS</last_name>
      <phone>021-54030254</phone>
      <email>ymliu@shxh-centerlab.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

